













COMPLETE MICROBIOME MAPPING




General Macroscopic Description

	Result	Markers
Stool Colour	Brown	Colour - Brown is the colour of normal stool. Other colours may indicate abnormal gut health.
Stool Form	Semi-formed	Form - Sample form is categorised using the Bristol stool chart. A comment on stool appearance can be found in the comments section.
Mucous	Not Detected	Mucous - Mucous production may indicate the presence of an infection and/or inflammation.
Occult Blood	Negative	Blood (Macro) - The presence of blood in the stool may be the result of several causes besides colorectal bleeding, including hemorrhoids or gastrointestinal infection.

Short Chain Fatty Acids	Result	Range	Units	
Short Chain Fatty Acids, Beneficial	16.3	> 13.6	umol/g	
Butyrate	7.4 *L	10.8 - 33.5	%	
Acetate	79.4 *H	44.5 - 72.4	%	
Propionate	10.5	0.0 - 32.0	%	
Valerate	2.6	0.5 - 7.0	%	

GIT Functional Markers	Result	Range	Units	
Calprotectin.	<5.0	0.0 - 50.0	ug/g	
Pancreatic Elastase	355.0	> 200.0	ug/g	
Secretory (slgA)	564.7	510.0 - 2040.0	ng/mL	
Zonulin	25.8	0.0 - 107.0	ng/mL	
Beta glucuronidase	5828.9	368.0 - 6266.0	U/g	
Steatocrit	<1.0	0.0 - 10.0	%	
a-Transglutaminase IgA	<20	0.0 - 100.0	units/L	

Microbiome Mapping Summary

Parasites & Worms	Bacteria & Viruses	Fungi and Yeasts
		

Key Phyla Microbiota

Firmicutes:Bacteroidetes Ratio

0.96 < 1.00

RATIO



Relative Commensal Abundance of the 6 Phyla groups can be found on page 4 of this report



P: 1300 688 522
E: info@nutripath.com.au

-.LEIGH GIBBS (STUDENT)
STUDENT
PRACTITIONER 4000

INGRID CLARKE
03-Jul-1974 **Female**

1/276 BRONTE ROAD
WAVERLEY NSW 2024

LAB ID : 3990451
UR NO. : 6271404
Collection Date : 28-May-2024
Received Date: 30-May-2024



3990451

Parasites and Worms.

Parasitic Organisms

Result	Range	Units	
<dl	< 1.0	x10 ⁵ org/g	●
<dl	< 1.0	x10 ⁵ org/g	●
<dl	< 1.0	x10 ⁵ org/g	●
<dl	< 1.0	x10 ⁵ org/g	●
<dl	< 1.0	x10 ⁵ org/g	●
<dl	< 1.0	x10 ⁵ org/g	●
<dl	< 5.0	x10 ⁵ org/g	●
<dl	< 1.0	x10 ⁵ org/g	●

Worms

Ancylostoma duodenale, Roundworm	Not Detected		
Ascaris lumbricoides, Roundworm	Not Detected	Necator americanus, Hookworm	Not Detected
Trichuris trichiura, Whipworm	Not Detected	Enterobius vermicularis, Pinworm	Not Detected
Enterocytozoon spp	Not Detected	Hymenolepis spp, Tapeworm	Not Detected
Strongyloides spp, Roundworm	Not Detected	Taenia species, Tapeworm	Not Detected

Comment: Not Detected results indicate the absence of detectable DNA in the sample for the worms reported.
NOTE: Reflex testing is performed on clinically indicated samples

Opportunistic Bacteria/Overgrowth

Result	Range	Units	
<dl	< 1.00	x10 ⁴ CFU/g	●
<dl	< 1.00	x10 ⁵ CFU/g	●
<dl	< 1.00	x10 ⁵ CFU/g	●
<dl	< 1.00	x10 ⁵ CFU/g	●
<dl	< 1.00	x10 ⁴ CFU/g	●
<dl	< 3.00	x10 ⁴ CFU/g	●
<dl	< 1.00	x10 ³ CFU/g	●
<dl	< 5.00	x10 ³ CFU/g	●
1.35	< 3.00	x10 ⁶ CFU/g	●
1.71	< 3.50	x10 ⁵ CFU/g	●
<dl	< 18.00	x10 ⁷ CFU/g	●
<dl	< 5.00	x10 ⁵ CFU/g	●

Potential Autoimmune Triggers

<dl	< 5.00	x10 ⁴ CFU/g	●
<dl	< 5.00	x10 ⁴ CFU/g	●
<dl	< 5.00	x10 ³ CFU/g	●
<dl	< 5.00	x10 ⁵ CFU/g	●
<dl	< 1.00	x10 ⁹ CFU/g	●
<dl	< 5.00	x10 ⁵ CFU/g	●
<dl	< 1.00	x10 ⁴ CFU/g	●
2.62	< 10.00	x10 ⁴ CFU/g	●

Fungi & Yeast

1.67	< 5.00	x10 ⁴ CFU/g	●
<dl	< 5.00	x10 ⁵ CFU/g	●
<dl	< 3.00	x10 ² CFU/g	●
<dl	< 3.00	x10 ³ CFU/g	●
<dl	< 1.00	x10 ³ CFU/g	●



3990451

Bacterial Pathogens	Result	Range	Units	
Aeromonas hydrophila.	<dl	< 1.00	x10 ³ CFU/g	
Campylobacter species.	<dl	< 1.00	x10 ⁵ CFU/g	
C. difficile, Toxin A	<dl	< 1.00	x10 ⁴ CFU/g	
C. difficile, Toxin B	<dl	< 1.00	x10 ⁴ CFU/g	
Enterohemorrhagic E. coli	<dl	< 1.00	x10 ⁵ CFU/g	
Enteroinvasive E. coli/Shigella	<dl	< 1.00	x10 ³ CFU/g	
Enterotoxigenic E. coli LT/ST	<dl	< 1.00	x10 ⁵ CFU/g	
Shiga-like Toxin E. coli stx1	<dl	< 1.00	x10 ⁴ CFU/g	
Shiga-like Toxin E. coli stx2	<dl	< 1.00	x10 ⁴ CFU/g	
Salmonella species.	<dl	< 1.00	x10 ⁵ CFU/g	
Vibrio species.	<dl	< 1.00	x10 ⁴ CFU/g	
Yersinia species.	<dl	< 1.00	x10 ⁵ CFU/g	
Helicobacter pylori	<dl	< 1.0	x10 ³ CFU/g	

Comment: Helico Pylori virulence factors will be listed below if detected POSITIVE

H.pylori Virulence Factor, babA	Not Detected	H.pylori Virulence Factor, cagA	Not Detected
H.pylori Virulence Factor, dupA	Not Detected	H.pylori Virulence Factor, iceA	Not Detected
H.pylori Virulence Factor, oipA	Not Detected	H.pylori Virulence Factor, vacA	Not Detected
H.pylori Virulence Factor, virB	Not Detected	H.pylori Virulence Factor, virD	Not Detected

Viral Pathogens	Result	Range	Units
Adenovirus 40/41	Not Detected		
Norovirus GI/II	Not Detected		
Rotavirus A	Not Detected		
Sapovirus (I,II,IV,V)	Not Detected		
Astrovirus (hAstro)	Not Detected		

Normal Bacterial GUT Flora	Result	Range	Units	
Bacteroides fragilis	1.0 *L	1.6 - 250.0	x10 ⁵ CFU/g	
Bifidobacterium species	6.4 *L	> 6.7	x10 ⁵ CFU/g	
Bifidobacterium longum	4.1 *L	> 5.2	x10 ⁵ CFU/g	
Enterococcus species	2.6	1.9 - 2000.0	x10 ³ CFU/g	
Escherichia species	2906.5	3.7 - 3800.0	x10 ⁴ CFU/g	
Lactobacillus species	21.9	8.6 - 6200.0	x10 ³ CFU/g	
Lactobacillus rhamnosus	1.2 *L	8.3 - 885.0	x10 ³ CFU/g	
Clostridium species	104.0 *H	5.0 - 50.0	x10 ⁷ CFU/g	
Oxalobacter formigenes	10.22	> 5.00	x10 ⁶ CFU/g	
Akkermansia muciniphila	4.72	1.00 - 50.00	x10 ⁷ CFU/g	
Faecalibacterium prausnitzii	261.1	200.0 - 3500.0	x10 ⁶ CFU/g	

Methodology:

GIT Functional markers performed by GCMS,EIA,FEIA.

Bacteriology,Virology,Fungi,Parasites & Worms performed by PCR,qPCR.






<dl = result below detectable limit. *H = Result greater than the reference range. *L = Result less than the reference range




3990451

Introduction:


Your gut microbiome is a collective name for the 40 trillion cells and up to 1000 microbial species that include bacteria, viruses, fungi, parasites, and archaea and reside in our gut. The number of gut bacterial cells is approximately equal to the total number of human cells in our body, so if we consider only cell counts, we are only about half human. In terms of gene counts, the microbiome contains about 200 times more genes than the human genome, making bacterial genes responsible for over 99% of our body's gene content! Of all the microbial communities in the human body, the gut microbiome is by far the most dense, diverse, and physiologically important ecosystem to our overall health.

Relative Commensal Abundance	Result	Range	Units
 Bacteroidetes Phylum	48.813*L	50.000 - 95.000	%
 Firmicutes Phylum	46.818*H	3.500 - 40.000	%
 Proteobacteria Phylum	4.102	0.500 - 12.500	%
 Verrucomicrobia Phylum	0.251	0.000 - 2.400	%
 Euryarchaeota Phylum	0.011	0.000 - 0.017	%
 Actinobacteria Phylum	0.005	0.001 - 4.818	%

Your Phyla:



Healthy Phyla:



References:

NOTE: Relative abundance reference ranges have been based on a healthy population study.

King CH, et., al. (2019) Baseline human gut microbiota profile in healthy people and standard reporting template. PLoS One. 2019 Sep 11;14(9):e0206484.



3990451

Pathogen Summary:

Macroscopy Comment

BROWN coloured stool is considered normal in appearance.

Faecal Occult Blood Negative:

Faecal occult blood has not been detected in this specimen. If the test result is negative and clinical symptoms persist, additional follow-up testing using other clinical methods is recommended.

Metabolism Comment

In a healthy gut Short Chain Fatty Acids (SCFAs) exhibited in the following proportions; Butyrate, Acetate, Propionate (16%:60%:24%).

The primary SCFAs butyrate, propionate and acetate are produced by predominant commensal bacteria via fermentation of soluble dietary fibre and intestinal mucus glycans.

Key producers of SCFAs include *Faecalibacterium prausnitzii*, *Akkermansia muciniphila*, *Bacteroides fragilis*, *Bifidobacterium*, *Clostridium* and *Lactobacillus* Spp.

The SCFAs provide energy for intestinal cells and regulate the actions of specialised mucosal cells that produce anti-inflammatory and antimicrobial factors, mucins that constitute the mucus barriers, and gut active peptides that facilitate appetite regulation and euglycemia. Abnormal SCFAs may be associated with dysbiosis, intestinal barrier dysfunction and inflammatory conditions.

LOW BUTYRATE LEVEL:

Butyrate is a short chain fatty acid that is extremely important for gut health. It is the main fuel source for gut cells, which helps keep the gut cell barrier intact, can reduce inflammation, and helps control appetite. Low levels of butyrate production have been observed in individuals with inflammatory bowel diseases, insufficient fibre intake, slow transit time, recent antibiotic therapy. Low butyrate may also be associated with an increased risk of colon cancer & constipation.

Consuming foods high in resistant starch has been shown to increase butyrate levels.

ELEVATED ACETATE LEVEL:

Acetate is the most abundant short chain fatty acid produced in the gut. It plays an important role in fat metabolism, glucose metabolism and the immune system. Several bacterial species can also convert acetate to butyrate. The consumption of fruits, vegetables, legumes and fibre are associated with increased short chain fatty acids, including acetate.

SCFA PRODUCTION TABLE

BACTERIA	BUTYRATE	PROPIONATE	ACETATE
<i>Akkermansia muciniphila</i>		▲▲▲	▲▲
<i>Anaerostipes caccae</i>	▲▲▲		
<i>Bacteroides</i> spp.		▲▲▲	
<i>Bifidobacterium</i> spp.		▲	▲▲▲
<i>Blautia obeum</i>		▲▲	▲▲▲
<i>Coprococcus eutactus</i>	▲		
<i>Escherichia coli</i>			▲
<i>Eubacterium rectale</i>	▲▲		
<i>Faecalibacterium prausnitzii</i>	▲▲▲		
<i>Lactobacillus</i> spp.	▲	▲	▲
<i>Roseburia homini</i>	▲▲		
<i>Ruminococcus bromii</i>	▲		▲
<i>Subdoligranulum variabile</i>	▲		

KEY

▲ Low Producers

▲▲ Moderate Producers

▲▲▲ High Producers



P: 1300 688 522
E: info@nutripath.com.au

-LEIGH GIBBS (STUDENT)
STUDENT
PRACTITIONER 4000

INGRID CLARKE
03-Jul-1974 **Female**

1/276 BRONTE ROAD
WAVERLEY NSW 2024

LAB ID : 3990451
UR NO. : 6271404
Collection Date : 28-May-2024
Received Date: 30-May-2024



3990451

GIT Markers Comment

PANCREATIC ELASTASE: Normal exocrine pancreatic function.
Pancreatic Elastase reflects trypsin, chymotrypsin, amylase and lipase activity.
This test is not affected by supplements of pancreatic enzymes.
Healthy individuals should be producing >500 ug/g of PE-1 under normal/healthy conditions.
PE-1 levels between 200 - 500 ug/g may indicate suboptimal production.
PE-1 levels <200 ug/g indicate clear inadequate production.
The clinician should therefore consider digestive enzyme supplementation if one or more of the following conditions is present:
Loose watery stools, Undigested food in the stools, Post-prandial abdominal pain, Nausea or colicky abdominal pain,
Gastroesophageal reflux symptoms, Bloating or food intolerance.

Testing performed by chemiluminescence immunoassay (CLIA).

CALPROTECTIN Normal:

Faecal calprotectin values <50 ug/g are not indicative of inflammation in the gastrointestinal tract. Subjects with low faecal calprotectin levels normally do not need to be further investigated by invasive procedures. In patients with strong clinical indications of intestinal inflammation, repeat testing may be useful.

Test performed by Phadia ELIA Fluorescence enzyme immunoassay (FEIA).

SECRETORY IGA NORMAL:

Secretory IgA is within range.

Secretory IgA represents the first line of defence of the gastrointestinal mucosa and is central to the normal function of the gastrointestinal tract as an immune barrier. Review this level with other pathogenic bacteria and normal commensal flora. Lower levels within reference range should be interpreted clinically.

ZONULIN NORMAL:

Zonulin is a protein that modulates intestinal barrier function. This results is considered normal.

BETA-GLUCURONIDASE NORMAL:

B-Glucuronidase is considered normal and is within reference range.

Phyla Microbiota Comment

FIRMICUTES (PHYLUM) ELEVATED:

DESCRIPTION:

Firmicutes are a phylum of diverse bacteria which are primarily grouped into classes, Bacilli, Clostridia, Erysipelotrichia and Negativicutes. They are found in various environments, including the intestinal tract, and the group includes some notable pathogens. Firmicutes are involved in energy resorption in the gut microbiome and levels may be affected by diet. Elevated levels and disturbance of gastrointestinal microbiome balance, particularly Firmicutes/Bacteroidetes ratio, have been associated with inflammation, obesity, diabetes and with a high sugar/ fat diet.

TREATMENT SUGGESTIONS: Consider using Bifidobacterium or Saccharomyces containing probiotics. It may also be suggested to optimise the patient diet. A lower fat diet may help to normalize Firmicutes levels.



P: 1300 688 522
E: info@nutripath.com.au

-.LEIGH GIBBS (STUDENT)
STUDENT
PRACTITIONER 4000

INGRID CLARKE
03-Jul-1974 **Female**

1/276 BRONTE ROAD
WAVERLEY NSW 2024

LAB ID : 3990451
UR NO. : 6271404
Collection Date : 28-May-2024
Received Date: 30-May-2024



3990451

Normal Bacterial Flora Comment

BACTEROIDES FRAGILIS LOW:

PHYLUM: Bacteroidetes

DESCRIPTION: Bacteroides fragilis is an anaerobic, Gram-negative bacterium. It is part of the normal microbiota of the human colon and is generally commensal. Bacteroides fragilis plays an intricate role in the human colon and usually has a beneficial relationship with the host. Low Bacteroides fragilis levels have been associated with inflammatory bowel disease and Crohn's.

TREATMENT SUGGESTIONS: Treatment may involve the use of probiotics and dietary modification.

BIFIDOBACTERIUM LONGUM LOW:

PHYLUM: Actinobacteria

DESCRIPTION:

Bifidobacterium longum is a Gram-positive, catalase-negative, rod-shaped bacterium present in the human gastrointestinal tract and one of the Bifidobacterium species. It can induce and regulate immune responses, reduce the expression of inflammatory cytokines, and maintain the normal intestinal barrier function.

Bifidobacterium longum is a clinically effective, well-established, multifunctional probiotic that has a long history of human use in alleviating gastrointestinal, immunological, and infectious diseases such as constipation, antibiotic associated diarrhoea, irritable bowel syndrome and ulcerative colitis. Low levels may be associated with irritable bowel syndrome, asthma, autism, depressive disorder and with pathogenic bacteria infection.

TREATMENT SUGGESTIONS: Treatment may involve the use of Bifidobacterium longum containing probiotics and treatment of any intestinal infections.

BIFIDOBACTERIUM SPECIES LOW:

PHYLUM: Actinobacteria

DESCRIPTION:

Bifidobacterium is a genus of gram-positive, nonmotile anaerobic bacteria that are ubiquitous inhabitants of the gastrointestinal tract and considered a probiotic. Bifidobacterium species prevent diarrhea and intestinal infections, alleviate constipation, and stimulate the immune system. Low levels may be associated with irritable bowel syndrome, asthma, autism, depressive disorder and with pathogenic bacterial infection.

TREATMENT SUGGESTIONS: Treatment may involve the use of Bifidobacterium containing probiotics and treatment of any intestinal infection.

LACTOBACILLUS SPECIES LOW NORMAL:

PHYLUM: Firmicutes

DESCRIPTION:

Lactobacillus species is below average.

Lactobacillus is a genus of Gram-positive rod-shaped, non-spore-forming bacteria which constitute a significantly important component of the human gastrointestinal system.

Lactobacillus exhibits a mutualistic relationship with the human body, as it protects the host against potential invasions by pathogens, and in turn, the host provides a source of nutrients. Lactobacilli are among the most common probiotic found in food such as yogurt, and it is diverse in its application to maintain gut health and to help treat ailments clinically such as diarrhea and obesity.

Lactobacillus species promote the anti-inflammatory response, thereby supporting the improvement of symptoms pertaining to asthma, chronic obstructive pulmonary disease, neuroinflammatory diseases, cardiovascular diseases, inflammatory bowel disease (IBD) and chronic infections in patients. Reduced levels increase the risk of infections and inflammation. Studies have also revealed that chronic psychological stress and alcohol use may be associated with a decrease in Lactobacillus species, as well as antibiotic / medication use.

TREATMENT SUGGESTIONS: Treatment may involve the use of Lactobacillus containing probiotics and treatment of any intestinal infections.



P: 1300 688 522
E: info@nutripath.com.au

-.LEIGH GIBBS (STUDENT)
STUDENT
PRACTITIONER 4000

INGRID CLARKE
03-Jul-1974 **Female**

1/276 BRONTE ROAD
WAVERLEY NSW 2024

LAB ID : 3990451
UR NO. : 6271404
Collection Date : 28-May-2024
Received Date: 30-May-2024



3990451

LACTOBACILLUS RHAMNOSUS LOW:

PHYLUM: Firmicutes

DESCRIPTION:

Lactobacillus Rhamnosus is a Gram-positive anaerobic bacterium and is one of the most widely used probiotic strains, of which various health effects are well documented including the prevention and treatment of gastro-intestinal infections and diarrhea and even preventing certain allergic symptoms.

Decreased Lactobacillus rhamnosus colonisation has been shown to decrease gastro-intestinal health, increasing the risk of gastro-intestinal infections and diarrhea as well as extra-intestinal infections including oral and respiratory health. Studies have also revealed that chronic psychological stress and alcohol use may be associated with a decrease in Lactobacillus species, as well as antibiotic / medication use.

TREATMENT SUGGESTIONS: Treatment may involve the use of Lactobacillus containing probiotics and treatment of any intestinal infections.

CLOSTRIDIUM SPECIES ELEVATED:

PHYLUM: Firmicutes

DESCRIPTION:

Clostridium is a genus of anaerobic, Gram-positive bacteria found in the environment and the intestinal tract. This genus includes several species and can utilize large amounts of nutrients that cannot be digested by host and produce short-chain fatty acids (SCFAs), which play a noticeable role in intestinal homeostasis. Colonisation of Clostridium species may be affected by diet (carbohydrate and protein in diet) and general health and may be protective against inflammation and infection. However, some species may act as potential pathogens. Elevated Clostridium species may indirectly damage the intestinal epithelial cells. Another symptom may include constipation.

TREATMENT SUGGESTIONS: Treatment may involve the use of probiotics, treatment of any intestinal infections and dietary modification (reduce consumption of different fibres, such as inulin, oligofructose, arabinoxylan, guar gum and starch).



3990451

The Four “R” Treatment Protocol

REMOVE	Using a course of antimicrobial, antibacterial, antiviral or anti parasitic therapies in cases where organisms are present. It may also be necessary to remove offending foods, gluten, or medication that may be acting as antagonists. Consider testing IgG96 foods as a tool for removing offending foods.	ANTIMICROBIAL	Oil of oregano, berberine, caprylic acid
		ANTIBACTERIAL	Liquorice, zinc carnosine, mastic gum, tribulus, berberine, black walnut, caprylic acid, oil of oregano
		ANTIFUNGAL	Oil of oregano, caprylic acid, berberine, black walnut
		ANTIPARASITIC	Artemesia, black walnut, berberine, oil of oregano
		ANTIVIRAL	Cat's claw, berberine, echinacea, vitamin C, vitamin D3, zinc, reishi mushrooms
		BIOFILM	Oil of oregano, protease
REPLACE	In cases of maldigestion or malabsorption, it may be necessary to restore proper digestion by supplementing with digestive enzymes.	DIGESTIVE SUPPORT	Betaine hydrochloride, tilactase, amylase, lipase, protease, apple cider vinegar, herbal bitters
REINOCULATE	Recolonisation with healthy, beneficial bacteria. Supplementation with probiotics, along with the use of prebiotics helps re-establish the proper microbial balance.	PREBIOTICS	Slippery elm, pectin, larch arabinogalactans
		PROBIOTICS	Bifidobacterium animalis subsp. lactis, lactobacillus acidophilus, lactobacillus plantarum, lactobacillus casei, bifidobacterium breve, bifidobacterium bifidum, bifidobacterium longum, lactobacillus salivarius, lactobacillus paracasei, lactobacillus rhamnosus, Saccharomyces boulardii
REPAIR & REBALANCE	Restore the integrity of the gut mucosa by giving support to healthy mucosal cells, as well as immune support. Address whole body health and lifestyle factors so as to prevent future GI dysfunction.	INTESTINAL MUCOSA IMMUNE SUPPORT	Saccharomyces boulardii, lauric acid
		INTESTINAL BARRIER REPAIR	L-Glutamine, aloe vera, liquorice, marshmallow root, okra, quercetin, slippery elm, zinc carnosine, Saccharomyces boulardii, omega 3 essential fatty acids, B vitamins
		SUPPORT CONSIDERATION	Sleep, diet, exercise, and stress management